Exposure of adolescent rats to oral methylphenidate: Preferential effects on extracellular norepinephrine and absence of sensitization and cross-sensitization to methamphetamine

Journal of Neuroscience

Volumn 22, Issue 16, 2002, Pages 7264-7271

  Kuczenski, Ronald ^a   Segal, David S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adolescent; Amphetamine; Attention deficit; Chronic; Dopamine; Methamphetamine; Methylphenidate; Norepinephrine

Indexed keywords

DOPAMINE; METHAMPHETAMINE; METHYLPHENIDATE; NORADRENALIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENTION DEFICIT DISORDER; CONTROLLED STUDY; DOPAMINE METABOLISM; HIPPOCAMPUS; LOCOMOTION; MALE; NONHUMAN; NORADRENALIN UPTAKE; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RAT;

EID: 0037104803     PISSN: 02706474     EISSN: None     Source Type: Journal    
DOI: 10.1523/jneurosci.22-16-07264.2002     Document Type: Article

References (75)

1. Andersen SL, Arvanitogiannis A, Pliakas AM, LeBlanc C, Carlezon Jr WA (2002) Altered responsiveness to cocaine in rats exposed to methylphenidate during development. Nat Neurosci 5:13-14.
2. Aoyama T, Kotaki H, Iga T (1990) Dose-dependent kinetics of methylphenidate enantiomers after oral administration of racemic methylphenidate to rats. J Pharmacobiol Dyn 13:647-652.
3. Arnsten AFT (2001) Dopaminergic and noradrenergic influences on cognitive functions mediated by prefrontal cortex. In: Stimulant Drugs and ADHD: Basic and Clinical Neuroscience (Solanto MV, Arnsten AFT, Castellanos FX, eds), pp 185-208. New York: Oxford UP.
4. Benet LZ, Mitchell JR, Sheiner LB (1990) Pharmacokinetics: The dynamics of drug absorption, distribution, and elimination. In: Goodman and Gilman's The Pharmacological Basis of Therapeutics (Gilman AG, Rall TW, Nies AS, Taylor P, eds), pp 3-32. New York: Pergamon.
5. Biederman J, Spencer T (1999) Attention-deficit/hyperactivity disorder (ADHD) as a noradrenergic disorder. Biol Psychiatry 46:1234-1242.
6. Biederman J, Wilens TE, Mick E, Spencer T, Faraone SV (1999) Pharmacotherapy of attention-deficit/hyperactivity disorder reduces risk for substance use disorder. Pediatrics 104:E201-E205.
7. Biederman J, Mick E, Faraone SV (2000) Age-dependent decline of symptoms of attention deficit hyperactivity disorder: Impact of remission definition and symptom type. Am J Psychiatry 157:816-818.
8. Brandon CL, Marinelli M, Baker LK, White FJ (2000) Adolescent exposure to a low dose of methylphenidate enhances reactivity to cocaine. Soc Neurosci Abstr 26:268.
9. Brandon CL, Marinelli M, Baker LK, White FJ (2001) Enhanced reactivity and vulnerability to cocaine following methylphenidate treatment in adolescent rats. Neuropsychopharmacology 25:651-661.
10. Challman TD, Lipsky JJ (2000) Methylphenidate: Its pharmacology and uses. Mayo Clin Proc 75:711-721.
11. Committee on Children with Disabilities (1996) Medication for children with attentional disorders. Pediatrics 98:301-304.
12. Doerge DR, Fogle CM, Paule MG, McCullagh M, Bajic S (2000) Analysis of methylphenidate and its metabolite ritalinic acid in monkey plasma by liquid chromatagraphy/electrospray ionization mass spectrometry. Rapid Commun Mass Spectrom 14:619-623.
13. Florin SM, Kuczenski R, Segal DS (1994) Regional extracellular norepinephrine responses to amphetamine and cocaine and effects of clonidine pretreatment. Brain Res 654:53-62.
14. Garland EJ (1998) Pharmacotherapy of adolescent attention deficit hyperactivity disorder: Challenges, choices, caveats. J Psychopharmacol 12:385-395.
15. Gaytan O, Al-Rahim S, Swann A, Dafny N (1997a) Sensitization to locomotor effects of methylphenidate in the rat. Life Sci 61:PL101-PL107.
16. Gaytan O, Ghelani D, Martin D, Swann A, Dafny N (1997b) Methylphenidate: Diurnal effects on locomotor and stereotypic behavior in the rat. Brain Res 777:1-12.
17. Gaytan O, Lewis C, Swann A, Dafny N (1999) Diurnal differences in amphetamine sensitization. Eur J Pharmacol 374:1-9.
18. Gaytan O, Yang P, Swann A, Dafny N (2000) Diurnal differences in sensitization to methylphenidate. Brain Res 864:24-39.
19. Gerasimov MR, Franceschi M, Volkow ND, Gifford A, Gatley SJ, Marsteller D, Molina PE, Dewey SL (2000) Comparison between intraperitoneal and oral methylphenidate administration: A microdialysis and locomotor activity study. J Pharmacol Exp Ther 295:51-57.
20. Goldman-Rakic PS, Muly III EC, Williams GV (2000) D1 receptors in prefrontal cells and circuits. Brain Res Rev 31:295-301.
21. Greenhill LL (2001) Clinical effects of stimulant medication in attention-deficit/hyperactivity disorder (ADHD). In: Stimulant Drugs and ADHD: Basic and Clinical Neuroscience (Solanto MV, Arnsten AFT, Castellanos FX eds), pp 31-71. New York: Oxford UP.
22. Hale TS, Hariri AR, McCracken JT (2000) Attention-deficit/hyperactivity disorder: Perspectives from neuroimaging. Ment Retard Dev Disabil Res Rev 6:214-219.
23. Hollander E, Evers M (2001) New developments in impulsivity. Lancet 358:949-950.
24. Kalivas PW, Duffy P (1993a) Time course of extracellular dopamine and behavioral sensitization to cocaine. I. Dopamine axon terminals. J Neurosci 13:266-275.
25. Kalivas PW, Duffy P (1993b) Time course of extracellular dopamine and behavioral sensitization to cocaine. II. Dopamine perikarya. J Neurosci 13:276-284.
26. Kuczenski R, Segal DS (1989) Concomitant characterization of behavioral and striatal neurotransmitter response to amphetamine using in vivo microdialysis. J Neurosci 9:2051-2065.
27. Kuczenski R, Segal DS (1992) Regional norepinephrine response to amphetamine using dialysis: Comparison to caudate dopamine. Synapse 11:164-169.
28. Kuczenski R, Segal DS (1997) Effects of methylphenidate on extracellular dopamine, serotonin, and norepinephrine: Comparison to amphetamine. J Neurochem 68:2032-2037.
29. Kuczenski R, Segal DS (2001) Locomotor effects of acute and repeated threshold doses of amphetamine and methylphenidate: Relative roles of dopamine and norepinephrine. J Pharmacol Exp Ther 296:876-883.
30. Laviola G, Adriani W, Livia Terranova M, Gerra G (1999) Psychobiological risk factors for vulnerability to psychostimulants in human adolescents and animal models. Neurosci Biobehav Rev 23:993-1010.
31. Loney J, Kramer JR, Salisbury H (2002) Medicated versus unmedicated ADHD children: Adult involvement with legal and illegal drugs. In: Diagnosis and Treatment of ADHD (Jensen P, Cooper J, eds), New York: American Medical Association.
32. McNamara CG, Davidson ES, Schenk S (1993) A comparison of the motor-activating effects of acute and chronic exposure to amphetamine and methylphenidate. Pharmacol Biochem Behav 45:729-732.
33. Mehta MA, Owen AM, Sahakian BJ, Mavaddat N, Pickard JD, Robbins TW (2000) Methylphenidate enhances working memory by modulating discrete frontal and parietal lobe regions in the human brain. J Neurosci 20:RC65.
34. Michelson D, Faries D, Wernicke J, Kelsey D, Kendrick K, Sallee FR, Spencer T, Atomoxetine ADHDSG (2001) Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: A randomized, placebo-controlled, dose-response study. Pediatrics 108:NIL33-NIL41.
35. Moll GH, Heinrich H, Trott GE, Wirth S, Rothenberger A (2000) Deficient intracortical inhibition in drug-naive children with attention-deficit hyperactivity disorder is enhanced by methylphenidate. Neurosci Lett 284:121-125.
36. Mordenti J (1986) Man versus beast: Pharmacokinetic scaling in mammals. J Pharmacol Sci 75:1028-1040.
37. National Institutes of Health Consensus Development Conference Statement (2000) Diagnosis and treatment of attention-deficit/hyperactivity disorder (ADHD). J Am Acad Child Adolesc Psychiatry 39:182-193.
38. Patrick KS, Markowitz JS (1997) Pharmacology of methylphenidate, amphetamine enantiomers and pemoline in attention-deficit hyperactivity disorder. Hum Psychopharmacol 12:527-546.
39. Patrick KS, Ellington KR, Breese GR (1984) Distribution of methylphenidate and p-hydroxymethylphenidate in rats. J Pharmacol Exp Ther 231:61-65.
40. Paulson PE, Robinson TE (1995) Amphetamine-induced time-dependent sensitization of dopamine neurotransmission in the dorsal and ventral striatum: A microdialysis study in behaving rats. Synapse 19:56-65.
41. Pierce RC, Kalivas PW (1997) A circuitry model of the expression of behavioral sensitization to amphetamine-like psychostimulants. Brain Res Rev 25:192-216.
42. Robbins TW (2000) Chemical neuromodulation of frontal-executive functions in humans and other animals. Exp Brain Res 133:130-138.
43. Robinson TE, Becker JB (1986) Enduring changes in brain and behavior produced by chronic amphetamine administration: A review and evaluation of animal models of amphetamine psychosis. Brain Res Rev 11:157-198.
44. Robinson TE, Berridge KC (1993) The neural basis of drug craving: An incentive-sensitization theory of addiction. Brain Res Rev 18:247-291.
45. Robinson TE, Whishaw IQ (1988) Normalization of extracellular dopamine in striatum following recovery from a partial unilateral 6-OHDA lesion of the substantia nigra: A microdialysis study in freely moving rats. Brain Res 450:209-224.
46. Safer DJ, Allen RP (1989) Absence of tolerance to the behavioral effects of methylphenidate in hyperactive and inattentive children. J Pediat 115:1003-1008.
47. Sagvolden T (2001) The spontaneously hypertensive rat as a model for ADHD. In: Stimulant Drugs and ADHD: Basic and Clinical Neuroscience (Solanto MV, Arnsten AFT, Castellanos FX, eds), pp 221-237. New York: Oxford UP.
48. Salamone JD, Cousins MS, Snyder BJ (1997) Behavioral functions of nucleus accumbens dopamine: Empirical and conceptual problems with the anhedonia hypothesis. Neurosci Biobehav Rev 21:341-359.
49. Sax KW, Strakowski SM (1998) Enhanced behavioral response to repeated D-amphetamine and personality traits in humans. Biol Psychiatry 44:1192-1195.
50. Scahill L, Chappell PB, Kim YS, Schultz RT, Katsovich L, Shepherd E, Arnsten AFT, Cohen DJ, Leckman JF (2001) A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry 158:1067-1074.
51. Schenk S, Davidson E (1998) Stimulant pre-exposure sensitizes rats and humans to the rewarding effects of cocaine. NIDA Res Monograph 169:56-82.
52. Segal DS, Kuczenski R (1987) Individual differences in responsiveness to single and repeated amphetamine administration: Behavioral characteristics and neurochemical correlates. J Pharmacol Exp Ther 242:917-926.
53. Segal DS, Kuczenski R (1994) Behavioral pharmacology of amphetamine. In: Amphetamine and Its Analogues: Psychopharmacology, Toxicology and Abuse (Cho AK, Segal DS, eds), pp 115-150. San Diego: Academic.
54. Sesack SR, Hawrylak VA, Matus C, Guido MA, Levey AI (1998) Dopamine axon varicosities in the prelimbic division of the rat prefrontal cortex exhibit sparse immunoreactivity for the dopamine transporter. J Neurosci 18:2697-2708.
55. Shaywitz SE, Hunt RD, Jatlow P, Cohen DJ, Young JG, Pierce RN, Anderson GM, Shaywitz BA (1982) Psychopharmacology of attention deficit disorder: Pharmacokinetic, neuroendocrine, and behavioral measures following acute and chronic treatment with methylphenidate. Pediatrics 69:688-694.
56. Solanto MV, Arnsten AFT, Castellanos FX (2001) The neuroscience of stimulant drugs in ADHD. In: Stimulant Drugs and ADHD: Basic and Clinical Neuroscience (Solanto MV, Arnsten AFT, Castellanos FX, eds), pp 355-379. New York: Oxford UP.
57. Sripada S, Gaytan O, Al-Rahim S, Swann A, Dafny N (1998) Dose-related effects of MK-801 on acute and chronic methylphenidate administration. Brain Res 814:78-85.
58. Strakowski SM, Sax KW (1998) Progressive behavioral response to repeated D-amphetamine challenge: Further evidence for sensitization in humans. Biol Psychiatry 44:1171-1177.
59. Strakowski SM, Sax KW, Rosenberg HL, DelBello MP, Adler CM (2001) Human response to repeated low-dose D-amphetamine: Evidence for behavioral enhancement and tolerance. Neuropsychopharmacology 25:548-554.
60. Swanson JM, Volkow ND (2002) Pharmacokinetic and pharmacodynamic properties of stimulants: Implications for the design of new treatments for ADHD. Behav Brain Res 130:73-78.
61. Swanson JM, Gupta S, Guinta D, Flynn D, Agler D, Lerner M, Williams L, Shoulson I, Wigal S (1999) Acute tolerance to methylphenidate in the treatment of attention deficit hyperactivity disorder in children. Clin Pharmacol Ther 66:295-305.
62. Szabo ST, Blier P (2001) Effect of the selective noradrenergic reuptake inhibitor reboxetine on the firing activity of noradrenaline and serotonin neurons. Eur J Neurosci 13:2077-2087.
63. Tanda G, Pontieri FE, Frau R, Di Chiara G (1997) Contribution of blockade of the noradrenaline carrier to the increase of extracellular dopamine in the rat prefrontal cortex by amphetamine and cocaine. Eur J Neurosci 9:2077-2085.
64. Taylor FB, Russo J (2001) Comparing guanfacine and dextroamphetamine for the treatment of adult attention-deficit/hyperactivity disorder. J Clin Psychopharmacol 21:223-228.
65. Taylor JR, Jentsch JD (2001) Stimulant effects on striatal and cortical dopamine systems involved in reward-related behavior and impulsivity: Implications for ADHD. In: Stimulant Drugs and ADHD: Basic and Clinical Neuroscience (Solanto MV, Arnsten AFT, Castellanos FX, eds), pp 104-133. New York: Oxford UP.
66. Thai DL, Yurasits LN, Rudolph GR, Perel JM (1999) Comparative pharmacokinetics and tissue distribution of the d-enantiomers of parasubstituted methylphenidate analogs. Drug Metab Dis 27:645-650.
67. Vanderschuren LJMJ, Kalivas PW (2000) Alterations in dopaminergic and glutamatergic transmission in the induction and expression of behavioral sensitization: A critical review of preclinical studies. Psychopharmacology 151:99-120.
68. Vitiello B, Severe JB, Greenhill LL, Arnold E, Abikoff H, Bukstein O, Elliott GR, Hechtman L, Jensen PS, Hinshaw S, March JS, Newcorn JH, Swanson JM, Cantwell DP (2001) Methylphenidate dosage for children with ADHD over time under controlled conditions: Lessons from the MTA. J Am Acad Child Adolesc Psychiatry 40:188-196.
69. Volkow ND, Wang GJ, Fowler JS, Gatley SJ, Logan J, Ding YS, Hitzemann R, Pappas N (1998) Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am J Psychiatry 155:1325-1331.
70. Volkow ND, Wang GJ, Fowler JS, Logan J, Gerasimov M, Maynard L, Ding YS, Gatley SJ, Gifford A, Franceschi D (2001) Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. J Neurosci 21:NIL1-NIL5.
71. Wargin W, Kilts PC, Gualtieri CT, Ellington KR, Mueller RA, Kraemer G, Breese GR (1983) Pharmacokinetics of methylphenidate in man, rat and monkey. J Pharmacol Exp Ther 226:382-386.
72. Wayment HK, Schenk JO, Sorg BA (2001) Characterization of extracellular dopamine clearance in the medial prefrontal cortex: Role of monoamine uptake and monoamine oxidase inhibition. J Neurosci 21:35-44.
73. White FJ (1996) Synaptic regulation of mesocorticolimbic dopamine neurons. Annu Rev Neurosci 19:405-436.
74. White FJ, Kalivas PW (1998) Neuroadaptations involved in amphetamine and cocaine addiction. Drug Alcohol Depend 51:141-153.
75. Wigal T, Swanson JM, Regino R, Lerner MA, Soliman I, Steinhoff K, Gurbani S, Wigal SB (1999) Stimulant medications for the treatment of ADHD: Efficacy and limitations. Ment Retard Dev Disabil Res Rev 5:215-224.